10-Q: Fortrea Holdings Inc. Q2 2026 Financial Update

Fortrea Holdings Inc. reports a decrease in Q2 2026 revenues and net loss, with ongoing restructuring efforts and a focus on clinical services.

Summary

• Fortrea Holdings Inc. reported revenues of $678.2 million for the three months ended June 30, 2026, a decrease of 4.5% compared to $710.3 million in the same period of 2025.
• For the six months ended June 30, 2026, revenues were $1,314.7 million, down 3.4% from $1,361.6 million in the prior year.
• The company reported a net loss of $13.2 million for the three months ended June 30, 2026, an improvement from a net loss of $374.9 million in the prior year.
• The six-month net loss was $36.8 million, compared to $937.8 million in the same period of 2025.
• Direct costs decreased by 6.6% for the quarter and 5.4% for the six months, improving as a percentage of revenue.
• Selling, general, and administrative expenses decreased significantly by 18.2% for the quarter and 17.8% for the six months.
• Restructuring and other charges decreased to $2.7 million for the quarter and $9.4 million for the six months.
• The company had $168.6 million in cash and cash equivalents as of June 30, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to declining revenues and continued net losses, despite some operational cost improvements and a reduction in the net loss compared to the prior year.

Positives

• Net loss improved significantly to $13.2 million for Q2 2026 from $374.9 million in Q2 2025.
• Six-month net loss improved to $36.8 million from $937.8 million in the prior year.
• Direct costs as a percentage of revenue decreased to 79.5% in Q2 2026 from 81.2% in Q2 2025.
• Selling, general, and administrative expenses saw a substantial decrease of 18.2% for the quarter.
• Cash provided by operating activities improved to $11.9 million for the six months ended June 30, 2026, from a use of $102.4 million in the prior year.
• The company has $447.7 million available for borrowing under its revolving credit facility as of June 30, 2026.

Negatives

• Revenues decreased by 4.5% for the quarter and 3.4% for the six months.
• Organic revenue decrease of 4.9% for the quarter and 4.0% for the six months, attributed to lower pass-through costs and reduced demand in the functional service provider business.
• The company reported a goodwill impairment of $309.1 million in Q2 2025 and $797.9 million for the six months ended June 30, 2025.
• Accumulated deficit stands at $(1,420.0) million as of June 30, 2026.

Risks

• The company is involved in legal proceedings, including a challenge to the appointment of its CFO, Jason Knoblauch, by Thermo Fisher Scientific Inc., Clario Holdings, Inc., and eResearch Technology, Inc.
• A purported shareholder class action complaint was filed in June 2025 alleging omissions and misrepresentations to investors.
• The drug development industry is subject to extensive regulation, and interpretations of applicable statutes and regulations could adversely affect the company.
• The company's dependence on third parties for critical services.
• Risks and expenses associated with international operations, including currency fluctuations and trade policies.
• Customer or therapeutic area concentrations could impact revenue.
• The company's ability to successfully implement its business strategies and execute its long-term value creation strategy.

Future Outlook

The company believes its existing cash, cash flows from operations, and credit facilities will be sufficient to cover its operational needs for at least the next 12 months. It routinely evaluates strategic opportunities, including potential acquisitions, joint ventures, or investments, and may access capital markets for debt or equity issuance.

Management Comments

• The Company disagrees with Plaintiffs allegations but is complying with the Courts order and intends to defend the action.
• The Company believes it has valid defenses to the claims alleged and intends to vigorously defend itself, but there is no guarantee that the Company will prevail.
• The Company does not believe that any liabilities resulting from claims and legal actions will have a material effect on its financial condition, results of operations or cash flows.

Industry Context

StockSavvy.ai notes that Fortrea's performance reflects broader trends in the contract research organization (CRO) sector, which is experiencing pressure on pricing and demand for certain services, while also seeing growth in specialized areas like clinical pharmacology.

Comparison to Industry Standards

• Fortrea's revenue decline of 3.4% year-over-year for the first six months of 2026 is slightly better than the average decline seen in some segments of the CRO market, which have faced headwinds.
• The significant improvement in net loss is a positive indicator, though the industry generally aims for profitability and positive net income.
• The company's focus on clinical services and clinical pharmacology aligns with industry trends prioritizing specialized expertise.
• Competitors like IQVIA and PPD (now part of Thermo Fisher Scientific) operate at a larger scale, but Fortrea's strategy emphasizes flexibility and tailored solutions.

Management Changes

Corporate Governance

Legal Proceedings

• Action filed by Thermo Fisher Scientific Inc., Clario Holdings, Inc., and eResearch Technology, Inc. challenging the appointment of Jason Knoblauch as CFO, alleging violation of restrictive covenants and retention of confidential information.
• A purported shareholder class action complaint filed in June 2025 alleging omissions and misrepresentations to investors, with an amended complaint filed and a motion to dismiss pending.
• The company believes it is in compliance with all applicable statutes and regulations, but acknowledges the potential for adverse interpretation by regulatory or judicial authorities.

Stakeholder Impact

• Shareholders: Continued net losses and revenue decline may impact stock price and investor confidence, though cost reductions and improved loss figures are positive signs.
• Employees: Restructuring actions may impact employee roles and morale, but also contribute to cost savings.
• Customers: Potential impact from legal proceedings related to key personnel, though the company is defending vigorously.
• Creditors: The company's ability to service its debt is supported by its liquidity and credit facilities, but continued losses could pose long-term risks.

Next Steps

• The company intends to defend the legal action challenging the appointment of its CFO.
• A hearing on the preliminary injunction motion for the CFO legal case is expected in early September.
• The company will continue to evaluate strategic opportunities, including potential acquisitions, joint ventures, or investments.
• The company will continue to monitor and manage its exposure to market risks, including foreign currency exchange rates and interest rates.

Key Dates

Recommendation

The company shows signs of operational improvement with reduced costs and a narrowing net loss, but the continued revenue decline and ongoing legal challenges present significant uncertainties. A 'hold' recommendation reflects a balanced view of these competing factors, suggesting investors await further clarity on the legal situation and a return to revenue growth.

Keywords

Contract Research Organization, Clinical Trials, Biopharmaceutical Development, Medical Device Development, Clinical Pharmacology, Drug Development Services, CRO, Phase I-IV Clinical Trials